Skip to Content

Dihydroergotamine Pregnancy and Breastfeeding Warnings

Dihydroergotamine is also known as: D.H.E. 45, Migranal

Dihydroergotamine Pregnancy Warnings

Use is contraindicated AU TGA pregnancy category: C US FDA pregnancy category: X Comment: -This drug should be discontinued immediately if a pregnancy occurs; if used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazards to the fetus.

Animal studies have revealed evidence of developmental toxicity including decreased fetal body weights and/or skeletal ossification, delayed skeletal ossification, and impaired reproductive function (decreased mating indices) in the offspring. These development effects occurred at doses below those producing maternal toxicity. As this drug induces uterine contractions, it may cause premature parturition or hypertonic labor. There are no controlled data in human pregnancy. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

See references

Dihydroergotamine Breastfeeding Warnings

Specific data documenting the concentration of this drug in human breast milk is lacking, but since ergot drugs are known to be excreted in human milk, it is likely this drug is present in breast milk. Potential adverse events in nursing infants may include vomiting, diarrhea, weak pulse, and unstable blood pressure. Ergot drugs are known to inhibit prolactin.

Use is contraindicated Excreted into human milk: Unknown (probably) Comment: -This drug should not be used while breastfeeding due to the potential for serious adverse events in nursing infants.

See references

References for pregnancy information

  1. "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.

References for breastfeeding information

  1. "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide